Betta Pharmaceuticals unit's BPI-572270 capsule wins US FDA clinical trial clearance
In short
Betta Pharmaceuticals said the US FDA has approved a clinical trial application for BPI-572270 capsules, filed by its wholly-owned subsidiary Jingyao Biology, for advanced solid tumours. The company described the drug as a self-developed pan-RAS “non-degrading molecular glue” inhibitor that showed strong inhibition of several RAS-mutant tumour cells in preclinical studies. Betta cautioned that drug development is long and costly, that trial and approval outcomes are uncertain, and that the programme will have no material impact on its near-term results.
Why it matters
The clearance allows a Chinese company's wholly-owned subsidiary to begin early-stage US testing of an internally developed RAS-targeted candidate, a step that would expand its oncology pipeline beyond China. The company itself framed the milestone as early and uncertain, saying it will not affect near-term performance, so any commercial effect lies years away.
Key facts
- Betta Pharmaceuticals announced that the US FDA approved the clinical trial application for BPI-572270 capsules. [ 1 , 2 , 3 ]
- The application was filed by Jingyao Biology, a wholly-owned subsidiary of Betta Pharmaceuticals. [ 1 , 3 ]
- The drug is intended for advanced solid tumours. [ 1 , 3 ]
- BPI-572270 is described as a self-developed pan-RAS “non-degrading molecular glue” inhibitor. [ 1 , 3 ]
- Preclinical studies showed strong inhibitory activity against several RAS-mutant tumour cells, according to the company. [ 1 , 3 ]
- The company said development cycles are long and costly, trial and approval outcomes are uncertain, and the programme will not materially affect recent results. [ 1 , 3 ]
Confirmed by several sources
- The US FDA approved the clinical trial application for BPI-572270 capsules, submitted by Betta Pharmaceuticals' wholly-owned subsidiary Jingyao Biology, for advanced solid tumours. [ 1 , 2 , 3 ]
- BPI-572270 is a self-developed pan-RAS “non-degrading molecular glue” inhibitor whose preclinical studies showed strong inhibition of multiple RAS-mutant tumour cells. [ 1 , 3 ]
- Betta Pharmaceuticals said trial and approval outcomes are uncertain and the drug will have no material impact on its near-term performance. [ 1 , 3 ]
Still unclear
- When the US trial will begin, how many patients it will enrol and where it will run. No document gives a start date, enrolment target or trial site.
- Which specific RAS mutations or tumour types the preclinical work covered. The documents refer only to “multiple RAS-mutant tumour cells” without naming mutations or indications.
- The FDA approval date itself. The documents report the company's October 7 announcement but do not state when the FDA decision was issued.